Their product is a chondroitin sulfate-based biopolymer platform that restores the protective layer of the urothelium, mimicking naturally occurring proteoglycans. They develop therapeutic products for soft tissue repair and rejuvenation, including dermis, cartilage, and other connective tissues damaged by disease and aging. The company targets locally delivered biopolymers to address unmet medical conditions such as interstitial cystitis, dry eye, post-surgical adhesion prevention, osteoarthritis, spinal disk disease, and wound repair. Glycologix is supported by grants from the NIH.